Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 6/20 | 1.00 |
| ▸ | OSBP | P22059 | 6/20 | 0.85 |
| ▸ | RORC | P51449 | 5/20 | 0.85 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.85 |
| ▸ | USP2 | O75604 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.85 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.85 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.84 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.81 |
| ▸ | CRYAB | P02511 | 1/20 | 0.80 |
| ▸ | HMGCR | P04035 | 1/20 | 0.80 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.80 |
| ▸ | ITGAV | P06756 | 1/20 | 0.80 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.80 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.80 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.80 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14771078 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| SCHEMBL17467018 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| SCHEMBL23385098 | 0.96 | GRIN1 (0.92) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| Cholesterol SCHEMBL27935905 | 0.93 | OSBP (0.91) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| Cholesterol SCHEMBL21681224 | 0.93 | OSBP (0.94) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| Cholesterol SCHEMBL454869 | 0.93 | OSBP (0.94) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| Cholesterol SCHEMBL454868 | 0.93 | OSBP (0.94) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| Cholesterol SCHEMBL28238054 | 0.93 | OSBP (0.89) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| Cholesterol SCHEMBL21632297 | 0.93 | OSBP (0.89) | GRIN1GRIN2AOSBPRORCOSBP2 | |
| Cholesterol SCHEMBL23365796 | 0.92 | OSBP (1.00) | GRIN1GRIN2AOSBPRORCOSBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245369-A2 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023114224-A1 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | SAGE THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, LLC | 2023-06-22 | — | — | US | disclosed |
| WO-2022261510-A1 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SAGE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3865135-A2 | NEUROACTIVE STEROIDS FOR USE IN THERAPY | Sage Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210147470-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10759828-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016057713-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014160441-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013036835-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147470-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | GRIN1 196/4885GRIN2A 90/4885OSBP 2286/4885 |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CYP21A2, CYP24A1, HSD17B2 | GRIN1 518/4885GRIN2A 155/4885OSBP 795/4885 |
| US-10759828-B2 | Neuroactive steroids, compositions, and uses thereof | CHRNB4, CHRNB3, MC2R | GRIN1 196/4885GRIN2A 90/4885OSBP 2286/4885 |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | GRIN1 199/4885GRIN2A 96/4885OSBP 2310/4885 |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | GRIN1 199/4885GRIN2A 96/4885OSBP 2310/4885 |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | GRIN1 3/4885GRIN2A 2/4885OSBP 47/4885 |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | GRIN1 3/4885GRIN2A 2/4885OSBP 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.